Role of gamma-secretase in human umbilical-cord derived mesenchymal stem cell mediated suppression of NK cell cytotoxicity

Cell Communication and Signaling

Volumn 12, Issue 1, 2014, Pages

  Chatterjee, Debanjana ^a   Marquardt, Nicole ^a   Tufa, Dejene Milkessa ^a   Beauclair, Guillaume ^a   Low, Hui Zhi ^a   Hatlapatka, Tim ^b   Hass, Ralf ^a   Kasper, Cornelia ^b,c   Von Kaisenberg, Constantin ^a   Schmidt, Reinhold Ernst ^a   Jacobs, Roland ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^c UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

Author keywords

Gamma secretase; IL 1 ; Immunosuppression; NK cell cytotoxicity; UC MSC

Indexed keywords

5' NUCLEOTIDASE; CD14 ANTIGEN; CD16 ANTIGEN; CD19 ANTIGEN; CD27 ANTIGEN; CD45 ANTIGEN; CD69 ANTIGEN; CD94 ANTIGEN; CYCLOOXYGENASE 2; ENDOGLIN; GAMMA SECRETASE; HLA DR ANTIGEN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; JANUS KINASE; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KYNURENINE; L SELECTIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; NATURAL KILLER CELL RECEPTOR NKG2A; NATURAL KILLER CELL RECEPTOR NKG2D; PRESENILIN; PROSTAGLANDIN E2; THY 1 ANTIGEN; INTERLEUKIN 1; SECRETASE;

ANTIGEN EXPRESSION; ARTICLE; BLOOD SAMPLING; CELL CULTURE; CELL DIFFERENTIATION; CELL FUNCTION; CELL INTERACTION; COCULTURE; CONTROLLED STUDY; DEGRANULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; MESENCHYMAL STEM CELL; MOLECULAR INTERACTION; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PROSTAGLANDIN RELEASE; PROTEIN DEGRADATION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UMBILICAL CORD; UPREGULATION; CELL COMMUNICATION; CYTOLOGY; CYTOTOXICITY TEST; K562 CELL LINE; MESENCHYMAL STROMA CELL; METABOLISM; NATURAL KILLER CELL; NEWBORN; PHYSIOLOGY;

AMYLOID PRECURSOR PROTEIN SECRETASES; CELL COMMUNICATION; CELL DEGRANULATION; CELLS, CULTURED; CYTOTOXICITY TESTS, IMMUNOLOGIC; DINOPROSTONE; HUMANS; INFANT, NEWBORN; INTERLEUKIN-1; K562 CELLS; KILLER CELLS, NATURAL; MESENCHYMAL STROMAL CELLS; PHENOTYPE; RECEPTORS, INTERLEUKIN-1; UMBILICAL CORD;

EID: 84907933279     PISSN: None     EISSN: 1478811X     Source Type: Journal    
DOI: 10.1186/s12964-014-0063-9     Document Type: Article

References (31)

1. Multilineage potential of adult human mesenchymal stem cells. MF Pittenger, Science 1999 284 143 147 10.1126/science.284.5411.143 10102814
2. Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. R Hass, C Kasper, S Böhm, R Jacobs, Cell Commun Signal 2011 9 12 10.1186/1478-811X-9-12 21569606
3. Growth and differentiation properties of mesenchymal stromal cell populations derived from whole human umbilical cord. I Majore, P Moretti, F Stahl, R Hass, C Kasper, Stem Cell Rev 2011 7 17 31 10.1007/s12015-010-9165-y 20596801
4. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. M Dominici, K Le Blanc, I Mueller, I Slaper-Cortenbach, F Marini, D Krause, R Deans, A Keating, D Prockop, E Horwitz, Cytotherapy 2006 8 315 317 10.1080/14653240600855905 16923606
5. Mesenchymal stem cells: a new strategy for immunosuppression? A Uccelli, V Pistoia, L Moretta, Trends Immunol 2007 28 219 226 10.1016/j.it.2007.03.001 17400510
6. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. WT Tse, JD Pendleton, WM Beyer, MC Egalka, EC Guinan, Transplantation 2003 75 389 397 10.1097/01.TP.0000045055.63901.A9 12589164
7. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. K Le Blanc, F Frassoni, L Ball, F Locatelli, H Roelofs, I Lewis, E Lanino, B Sundberg, ME Bernardo, M Remberger, G Dini, RM Egeler, A Bacigalupo, W Fibbe, O Ringdén, Lancet 2008 371 1579 1586 10.1016/S0140-6736(08)60690-X 18468541
8. Innate or adaptive immunity? The example of natural killer cells. E Vivier, DH Raulet, A Moretta, M Caligiuri, L Zitvogel, LL Lanier, WM Yokoyama, S Ugolini, Science 2011 331 44 49 10.1126/science.1198687 21212348
9. CD16-CD56+ natural killer cells after bone marrow transplantation. R Jacobs, M Stoll, G Stratmann, R Leo, H Link, RE Schmidt, Blood 1992 79 3239 3244 1375847
10. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. L Ruggeri, M Capanni, E Urbani, K Perruccio, WD Shlomchik, A Tosti, S Posati, D Rogaia, F Frassoni, F Aversa, MF Martelli, A Velardi, Science 2002 295 2097 2100 10.1126/science.1068440 11896281
11. Mesenchymal stem cells for graft-versus-host disease: a double edged sword? F Vianello, F Dazzi, Leukemia 2008 22 463 465 10.1038/leu.2008.25 18335000
12. Interactions between human mesenchymal stem cells and natural killer cells. PA Sotiropoulou, SA Perez, AD Gritzapis, CN Baxevanis, M Papamichail, Stem Cells 2006 24 74 85 10.1634/stemcells.2004-0359 16099998
13. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. GM Spaggiari, A Capobianco, H Abdelrazik, F Becchetti, MC Mingari, L Moretta, Blood 2008 111 1327 1333 10.1182/blood-2007-02-074997 17951526
14. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. GM Spaggiari, A Capobianco, S Becchetti, MC Mingari, L Moretta, Immunobiology 2006 107 1484 1490
15. Effective treatment of severe steroid-resistant acute graft-versus-host disease with umbilical cord-derived mesenchymal stem cells. K-H Wu, C-K Chan, C Tsai, Y-H Chang, M Sieber, T-H Chiu, M Ho, C-T Peng, H-P Wu, J-L Huang, Transplantation 2011 91 1412 1416 10.1097/TP.0b013e31821aba18 21494176
16. IFN-γ stimulated human umbilical-tissue-derived cells potently suppress NK activation and resist NK-mediated cytotoxicity in vitro. C Noone, A Kihm, K English, S O'Dea, BP Mahon, Stem Cells Dev 2013 22 3003 3014 10.1089/scd.2013.0028 23795941
17. Interleukin-1 receptor type 1 is a substrate for gamma-secretase-dependent regulated intramembrane proteolysis. BM Elzinga, C Twomey, JC Powell, F Harte, JV McCarthy, J Biol Chem 2009 284 1394 1409 10.1074/jbc.M803108200 18996842
18. An unusual CD56brightCD16low NK cell subset dominates the early posttransplant period following HLA-matched hematopoietic stem cell transplantation. N Dulphy, P Haas, M Busson, S Belhadj, R Peffault de Latour, M Robin, M Carmagnat, P Loiseau, R Tamouza, C Scieux, C Rabian, JP Di Santo, D Charron, A Janin, G Socie, A Toubert, J Immunol 2008 181 2227 2237 10.4049/jimmunol.181.3.2227 18641363
19. NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations/: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. S Nguyen, N Dhedin, J Vernant, M Kuentz, JA Al, N Rouas-freiss, ED Carosella, A Boudifa, P Debre, V Vieillard, CD Nkga, Blood 2005 105 4135 4142 10.1182/blood-2004-10-4113 15687235
20. Presenilins and the gamma-secretase: still a complex problem. DH Small, DW Klaver, L Foa, Mol Brain 2010 3 7 10.1186/1756-6606-3-7 20181106
21. The many substrates of presenilin/γ-secretase. A Haapasalo, D Kovacs, J Alzheimers Dis 2012 25 3 28
22. Roles of the NKG2D immunoreceptor and its ligands. DH Raulet, Nat Rev Immunol 2003 3 781 790 10.1038/nri1199 14523385
23. JNK MAP kinase activation is required for MTOC and granule polarization in NKG2D-mediated NK cell cytotoxicity. C Li, B Ge, M Nicotra, JNH Stern, HD Kopcow, X Chen, JL Strominger, Proc Natl Acad Sci U S A 2008 105 3017 3022 10.1073/pnas.0712310105 18287025
24. Human mesenchymal stem cells modulate allogeneic immune cell responses. S Aggarwal, MF Pittenger, Blood 2005 105 1815 1822 10.1182/blood-2004-04-1559 15494428
25. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. R Meisel, A Zibert, M Laryea, U Göbel, W Däubener, D Dilloo, Blood 2004 103 4619 4621 10.1182/blood-2003-11-3909 15001472
26. Pre-treatment with IL-1β enhances the efficacy of MSC transplantation in DSS-induced colitis. H Fan, G Zhao, L Liu, F Liu, W Gong, X Liu, L Yang, J Wang, Y Hou, Cell Mol Immunol 2012 9 473 481 10.1038/cmi.2012.40 23085948
27. The potential use of mesenchymal stem cells in hematopoietic stem cell transplantation. E-J Kim, N Kim, S-G Cho, Exp Mol Med 2013 45 2 10.1038/emm.2013.2 23306700
28. Allelic polymorphism synergizes with variable gene content to individualize human KIR genotype. HG Shilling, LA Guethlein, NW Cheng, CM Gardiner, R Rodriguez, D Tyan, P Parham, J Immunol 2002 168 2307 2315 10.4049/jimmunol.168.5.2307 11859120
29. Optimization of culture conditions for the expansion of umbilical cord-derived mesenchymal stem or stromal cell-like cells using xeno-free culture conditions. T Hatlapatka, P Moretti, A Lavrentieva, R Hass, N Marquardt, R Jacobs, C Kasper, Tissue Eng Part C Methods 2011 17 485 493 10.1089/ten.tec.2010.0406 21166520
30. Specific release of proteoglycans from human natural killer cells during target lysis. RE Schmidt, RP MacDermott, GT Bartley, M Bertovich, DA Amato, KF Austen, SF Schlossman, RL Stevens, Nature 1985 318 289 10.1038/318289a0 4069203
31. Calculation of lytic units for the expression of cell-mediated cytotoxicity. J Bryant, R Day, TL Whiteside, RB Herberman, J Immunol Methods 1992 146 91 103 10.1016/0022-1759(92)90052-U 1735786